CSIMarket Company Name, Ticker, Competitors, else..
 
Taysha Gene Therapies Inc   (NASDAQ: TSHA)
 
Price: $5.6900 $-0.08 -1.386%
Day's High: $5.775000095367432 Week Perf: -8.23 %
Day's Low: $ 5.53 30 Day Perf: -2.9 %
Volume (M): 2,062,154 52 Wk High: $ 7.30
Volume (M$): $ 0 52 Wk Avg: $5.13
Open: $5.74 52 Wk Low: $2.71



 Market Capitalization (Millions $) 2,086
 Shares Outstanding (Millions) 367
 Employees 99
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -130
 Cash Flow (TTM) (Millions $) 160
 Capital Exp. (TTM) (Millions $) 1

Business Description


Taysha Gene Therapies Inc is a clinical-stage gene therapy company focused on discovering, developing, and commercializing potential curative treatments for severe genetic disorders. Founded in 2020, the company utilizes its proprietary technology platform to develop transformative gene therapies for various neurological and lysosomal storage disorders. Taysha aims to address the underlying genetic cause of these disorders by delivering corrected genes or gene-modifying technologies to patients. The company is committed to advancing the field of gene therapy and improving the lives of patients suffering from debilitating genetic diseases.


   Company Address: 3000 Pegasus Park Drive Dallas 75247 TX
   Company Phone Number: 612-0000   Stock Exchange / Ticker: NASDAQ TSHA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ATRA   -5.92%    
BDTX   -2.55%    
IMCR   -0.79%    
IPSC   -3.3%    
KRYS        5.16% 
RGNX        17.94% 
• View Complete Report
   



Shares

Taysha Gene Therapies Enhances Talent Acquisition Strategy with Stock Options Amid Industry Shifts

Published Fri, May 2 2025 12:00 PM UTC

In a significant move reflecting its commitment to talent acquisition and retention, Taysha Gene Therapies, Inc. a clinical-stage biotechnology company dedicated to advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases affecting the central nervous system (CNS), announced on May 1, 2025, the grant of a stock option to a new employee. This ...
Shares

Taysha Gene Therapies Strengthens Talent Acquisition with New Stock Options Amid Market Challenges,

Published Fri, Feb 7 2025 1:00 PM UTC

Taysha Gene Therapies Reinforces Talent Acquisition Strategy with New Stock Option Grants Amid Challenging Market ConditionsIn a strategic move to attract and retain top talent, Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a leading clinical-stage biotechnology firm, has announced the granting of stock options to three new employees. The company s announcement on February 7,...
Shares

Taysha Gene Therapies Offers Inducement Stock Options Amid Talent Acquisition Strategy and Financial Recovery

Published Fri, Dec 6 2024 1:00 PM UTC

In a strategic move to bolster its workforce amid ongoing financial challenges, Taysha Gene Therapies, Inc. (Nasdaq: TSHA) has announced an inducement grant for a new employee in conjunction with its efforts to attract top talent. The Dallas-based clinical-stage biotechnology company, which specializes in developing adeno-associated virus (AAV)-based gene therapies for sever...
Management Announcement

Taysha Gene Therapies Strives for Talent Amidst Financial Turmoil: A Path to Recovery or a Risky Gamble,

Published Fri, Nov 1 2024 8:31 PM UTC

Taysha Gene Therapies: A Balancing Act Between Talent Acquisition and Financial StrugglesIn the ever-evolving landscape of biotechnology, Taysha Gene Therapies, Inc. (NASDAQ: TSHA) has recently taken center stage for a series of significant moves that highlight both ambition and concern. On November 1, 2024, the company’s Compensation Committee granted stock options amoun...
Financing Agreement

Taysha Gene Therapies Bolsters Workforce with Inducement Grants Despite Financial Challenges Under Nasdaq Rule 5635(c)(4),

Published Fri, Oct 4 2024 12:01 PM UTC

Taysha Gene Therapies, Inc. (NASDAQ: TSHA), a clinical-stage biotechnology company dedicated to advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), has made noteworthy movements on its executive compensation strategy as well as highlighted increasing financial challenges.On October 1, 2024, Tayshans C...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 279.23
Price to Sales (Expected) -
Price to Book 9.84
PEG (TTM) -

Financial Strength Current
Quick Ratio 13.76
Working Capital Ratio 14.04
Leverage Ratio (MRQ) 0.42
Total Debt to Equity 0.23
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.39 $
Revenues (TTM) 0.02 $
Cash Flow (TTM) 0.44 $
Cash 0.75 $
Book Value 0.58 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,311,879
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.